Scientific Advisory Board

Sid Aaron, Ph.D.; Genetic Toxicology
Sid provides MBR with program review and issue management in genetic toxicology.  He has more than 25 years of toxicology experience in private industry (pharmaceutical and chemical) and government (USEPA), and uses these experiences to provide clients with a full range of toxicological advice and consulting through his company, Sid Aaron Consultants.  He has held positions at Pfizer/Pharmacia/Upjohn including Director of Emerging Technologies, Director of Investigative Toxicology, Head of Genetic Toxicology, Distinguished Scientist, and Pharmacia Fellow.  Sid has experience working with regulatory agencies in the USA, Europe, and Japan.  He is recipient of the Alexander Hollaender award from the Environmental Mutagen Society, and is a diplomat of the American Board of Toxicology since 1988.

Sid received his Ph.D. in Biochemistry/Chemical Engineering from Louisiana State University.

Charles Piper, Ph.D.; Genetic Toxicology
Chuck provides program review and support to MBR’s genetic toxicology program.  He has more than 20 years of experience in the pharmaceutical industry with Searle/Monsanto, and has been an independent consultant during the last five years.  He has broad experience and expertise in pharmaceutical R&D. At Searle/Monsanto he held several executive positions in Product Safety, Project Management, and Clinical Research.  Chuck was the Senior Scientist for the genetic toxicology program at Searle, and he was also a manager in the Toxicology Department at Hazleton Laboratories (now Covance), responsible for the mutagenicity and in vitro toxicology section.

Chuck received a Ph.D. from Washington State University in cellular immunology and was certified as a Diplomat by the American Board of Toxicology.

James Longstreth, Ph.D.; Pharmacokinetics and Metabolism
James is responsible for supporting the pharmacokinetic (PK) and toxicokinetic (TK) aspects of drug discovery, development, and life cycle management.  His expertise is in the design, implementation, and analysis of animal and human trials for the identification of the time courses of critical indicators of a drug’s presence, performance, and toxicity, integrating PK/TK parameters with pharmacodynamic findings.  Jim is founder and president of Longstreth & Associates, Inc.  He has also held a number of scientific positions at Searle/Monsanto.

Jim received his Ph.D. in biomedical engineering from The Johns Hopkins University.